Market Overview

Regeneron Pharmaceuticals Spokesperson Declines Comment on Earlier Takeover Chatter

Share:
Related REGN
Strength Seen in Arena Pharmaceuticals (ARNA): Stock Up 5.4%
Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt
Stock Indexes Grip Small Gains, But This New Leader Swings Higher (Investor's Business Daily)
Related SNY
Why You Should Add Novo Nordisk Stock to Your Portfolio
Shire (SHPG) Receives MAA Validation for Veyvondi by EMA

Regeneron (NASDAQ: REGN) spokesperson Peter Dworkin, while declining comment on earlier takeover chatter involving Sanofi (NYSE: SNY), did say that the two companies have a solid working relationship and have stated it would be advantageous to keep the relationship going as it is now, as separate companies.

Sanofi is Regeneron's largest shareholder currently. There is a standstill agreement in place preventing Sanofi from acquiring more than 30% of Regeneron's shares.

Regeneron shares spiked to a high of $145.81 on Thursday.

Posted-In: News Rumors M&A Movers

 

Related Articles (REGN + SNY)

View Comments and Join the Discussion!